Genmab A/S
GMAB · NASDAQ Global Select · USD
55,80USD
+2,17 (+4,05 %)Stand 9. Nov., 21:00
Vorbörslich55,27−0,53 (−0,95 %)4:07 ET
Kennzahlen
- Eröffnung
- 54,32
- Vortag
- 53,63
- Tagesspanne
- 53,33 – 55,91
- 52 Wochen
- 23,62 – 59,97
- Volumen
- 5,1 Mio.
- Ø Volumen
- 3,55 Mio.
- Börsenwert
- 34,31 Mrd. $
- KGV
- 46,5
- Gewinn je Aktie (TTM)
- 1,17
- Dividendenrendite
- 0,0 %
- Beta
- 0,6
- Nächste Zahlen
- 16. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 3,72 Mrd. | 21,53 Mrd. | 16,47 Mrd. | 14,51 Mrd. | 8,42 Mrd. |
| Herstellungskosten | 309,24 Mio. | 985 Mio. | 226 Mio. | 0 | 0 |
| Bruttogewinn | 3,41 Mrd. | 20,54 Mrd. | 16,25 Mrd. | 14,51 Mrd. | 8,42 Mrd. |
| Forschung und Entwicklung | 1,56 Mrd. | 9,75 Mrd. | 7,63 Mrd. | 5,56 Mrd. | 4,18 Mrd. |
| Vertrieb und Verwaltung | 602,47 Mio. | 3,79 Mrd. | 3,3 Mrd. | 2,68 Mrd. | 1,28 Mrd. |
| Operatives Ergebnis | 1,25 Mrd. | 6,7 Mrd. | 5,32 Mrd. | 6,27 Mrd. | 2,95 Mrd. |
| EBITDA | 1,34 Mrd. | 9,7 Mrd. | 6 Mrd. | 7,35 Mrd. | 4,18 Mrd. |
| Nettogewinn | 963,76 Mio. | 7,84 Mrd. | 4,35 Mrd. | 5,45 Mrd. | 2,96 Mrd. |
| Gewinn je Aktie (verwässert) | 1,54 | 12,14 | 6,60 | 8,26 | 4,48 |
Bewertung
Letzte 12 Monate
- KGV
- 46,5
- Kurs-Umsatz-Verhältnis
- 7,9
- Kurs-Buchwert-Verhältnis
- 5,3
- PEG
- -0,6
- Bruttomarge
- 92,6 %
- Operative Marge
- 30,5 %
- Nettomarge
- 16,9 %
- Verschuldungsgrad
- 0,8
- EV/EBITDA
- 27,0
- Eigenkapitalrendite
- 12,3 %
- Kapitalrendite (ROIC)
- 10,3 %
- Free-Cashflow-Rendite
- 2,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 91,7 % | 95,4 % | 98,6 % | 100,0 % | 100,0 % |
| Operative Marge | 33,6 % | 31,1 % | 32,3 % | 43,2 % | 35,1 % |
| Nettomarge | 25,9 % | 36,4 % | 26,4 % | 37,6 % | 35,1 % |
| KGV | 19,9 | 12,4 | 32,6 | 35,3 | 57,2 |
| Kurs-Umsatz-Verhältnis | 5,1 | 4,5 | 8,6 | 13,3 | 20,1 |
| Kurs-Buchwert-Verhältnis | 3,3 | 2,6 | 4,5 | 7,1 | 7,6 |
| Verschuldungsgrad | 0,9 | 0,0 | 0,0 | 0,0 | 0,0 |
| Liquidität 3. Grades | 2,0 | 5,2 | 13,3 | 15,5 | 14,5 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 22,86 Mrd. | 88,33 Mrd. | 127,61 Mrd. | 183,16 Mrd. | 160,59 Mrd. |
| EV/EBITDA | 17,1 | 9,1 | 21,3 | 24,9 | 38,4 |
| Eigenkapitalrendite | 16,5 % | 21,4 % | 13,8 % | 20,0 % | 13,3 % |
| Kapitalrendite (ROIC) | 8,5 % | 14,1 % | 12,5 % | 17,3 % | 9,6 % |
| Free-Cashflow-Rendite | 6,0 % | 7,8 % | 4,9 % | 1,9 % | 1,2 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −82,7 % | +30,7 % | +13,6 % | +72,3 % | −16,8 % |
| Bruttogewinn | −83,4 % | +26,4 % | +12,0 % | +72,3 % | −16,8 % |
| Operatives Ergebnis | −81,3 % | +26,0 % | −15,1 % | +112,2 % | −53,2 % |
| Nettogewinn | −87,7 % | +80,2 % | −20,2 % | +84,4 % | −37,9 % |
| Gewinn je Aktie | −87,3 % | +83,8 % | −20,1 % | +84,4 % | −38,0 % |
| Freier Cashflow | −84,8 % | +8,3 % | +94,8 % | +81,9 % | −67,7 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 14Kaufen
- 3Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
50,60
Durchschnitt · −9,32 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 4,48 Mrd. | 5,42 Mrd. | 6,92 Mrd. |
| Umsatz (Tief – Hoch) | 4,28 Mrd. – 4,86 Mrd. | 5,25 Mrd. – 5,73 Mrd. | 5,56 Mrd. – 8,16 Mrd. |
| Gewinn je Aktie (Ø) | 1,18 | 1,75 | 2,80 |
| Gewinn je Aktie (Tief – Hoch) | 1,06 – 1,46 | 1,54 – 2,23 | 1,69 – 3,46 |
| Analysten | 7 | 7 | 13 |
Letzte Änderungen
- Morgan Stanley30. Okt. 2026Equal Weight
- Guggenheim30. Okt. 2026Buy
- HC Wainwright & Co.29. Okt. 2026Buy
- Truist Securities29. Okt. 2026Buy
- JP Morgan26. Okt. 2026Neutral → Overweight
- TD Cowen26. Okt. 2026Buy
- Guggenheim7. Okt. 2026Buy
- HC Wainwright & Co.7. Okt. 2026Buy
Quartalszahlen
Nächste Zahlen: 16. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,36 | 0,37 | 0,15 | 0,46 | 0,48 | 0,39 | 0,23 | 0,36 |
| Gewinn je Aktie · Tatsächlich | 0,56 | 0,54 | 0,09 | 0,05 | 0,65 | 0,54 | 0,31 | 0,57 |
| Abweichung | +55,56 % | +45,95 % | −42,00 % | −89,13 % | +35,42 % | +38,46 % | +34,78 % | +58,33 % |
| Umsatz · Tatsächlich | 1,19 Mrd. | 1,16 Mrd. | 896 Mio. | 1,06 Mrd. | 1,02 Mrd. | 924,81 Mio. | 725,99 Mio. | 895,8 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 1. Mai 20185:1
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 16,70 %
- Investoren mit 13F-Meldung
- 307
Größte Investoren
- PARADIGM BIOCAPITAL ADVISORS LP2,14 %13,13 Mio.
- ORBIS ALLAN GRAY LTD1,85 %11,37 Mio.
- ALLIANCEBERNSTEIN L.P.1,41 %8,64 Mio.
- DEERFIELD MANAGEMENT COMPANY, L.P.1,12 %6,87 Mio.
- DEEP TRACK CAPITAL, LP0,92 %5,65 Mio.
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP0,81 %4,98 Mio.
- BLACKROCK, INC.0,76 %4,67 Mio.
- SOFINNOVA INVESTMENTS, INC.0,66 %4,05 Mio.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Führung
- Jan van de WinkelCo-Founder, President & Chief Executive Officer
- Rayne WallerExecutive Vice President & Chief Technical Operations Officer
- Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer
- Judith V. KlimovskyExecutive Vice President & Chief Development Officer
- Tahamtan AhmadiExecutive Vice President, Chief Medical Officer & Head of Experimental Medicines
- Anthony PaganoExecutive Vice President & Chief Financial Officer
- CEO
- Jan van de Winkel
- Mitarbeitende
- 3.119
- Hauptsitz
- Copenhagen, CD, DK
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 1. Juni 2009
- Website
- genmab.com
Nachrichten
- Seeking Alpha · 5. Nov., 17:54Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
- MarketBeat · 5. Nov., 15:15What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
- GlobeNewsWire · 4. Nov., 9:00Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
- CNBC · 3. Nov., 4:35A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
- Seeking Alpha · 28. Okt., 17:30Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript
- MarketBeat · 28. Okt., 17:05Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
- Benzinga · 28. Okt., 13:44Genmab Stock Hits 52-Week High - Here's Why
- Barrons · 28. Okt., 13:21Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
- Business Wire · 28. Okt., 9:41Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
- GlobeNewsWire · 28. Okt., 9:40Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.